<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999631</url>
  </required_header>
  <id_info>
    <org_study_id>CMN001</org_study_id>
    <nct_id>NCT04999631</nct_id>
  </id_info>
  <brief_title>SADBE for Congenital Melanocytic Nevi</brief_title>
  <official_title>Neoadjuvant Squaric Acid Dibutylester Treatment of Melanocytes in Congenital Melanocytic Nevi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the safety and efficacy topical squaric acid dibutylester (SADBE) for the&#xD;
      neoadjuvant treatment of congenital melanocytic nevi (CMN).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with CMN and plans for elective surgical resection of their nevi will be enrolled in&#xD;
      the study. Two clinically similar areas within the planned excision site will be identified,&#xD;
      marked and treated with SADBE or the placebo solution. Following surgical resection, samples&#xD;
      from the excised nevi will be taken and assessed for number of melanocytes. Incidence of&#xD;
      adverse events will also be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2027</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two areas of the subject's nevus will be marked. Study medication will be applied to one area. Placebo ethanol solution will be applied to the other area. Area to be treated will be randomized among subjects. Both areas will be monitored and following surgery, samples will be obtained. Area to be treated vs area that will serve as control will be randomized.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Assessors will be blinded on what area received the study cream and what area received the placebo ethanol solution.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of melanocytes per mm2</measure>
    <time_frame>12 weeks</time_frame>
    <description>The number of melanocytes present in the biopsy specimen will be measured. b. Assessment of pigment within stratum corneum, epidermis, and dermis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>The frequency of adverse events from each treatment arm will be compared.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical appearance of nevi</measure>
    <time_frame>12 weeks</time_frame>
    <description>Treated areas will be compared for pigmentation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Congenital Melanocytic Nevus</condition>
  <arm_group>
    <arm_group_label>Squaric Acid Dibutyl Ester (SADBE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following sensitization, subjects will apply 0.2% SADBE in ethanol to a predetermined area of their nevus 3 times per week for 12 weeks, with adjustment of frequency depending on response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will apply an ethanol solution to a specified area of the nevus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Squaric Acid Dibutyl Ester</intervention_name>
    <description>Topical squaric acid dibutyl ester (SADBE) dissolved in ethanol at 0.2% concentration.</description>
    <arm_group_label>Squaric Acid Dibutyl Ester (SADBE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol Solution</intervention_name>
    <description>Control</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  Subject or parents willing and able to give informed consent, and assent as&#xD;
             appropriate.&#xD;
&#xD;
          -  Patients who have a clinical diagnosis of CMN with plans for elective non-urgent&#xD;
             excision of part or all of their nevus, with nevus surface area of &gt; 6 cm2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunosuppressive therapy with glucocorticoid or other systemic immunosuppressant&#xD;
             within 4 weeks of recruitment (except for inhaled corticosteroids for asthma).&#xD;
&#xD;
          -  History of malignancy.&#xD;
&#xD;
          -  History of organ transplantation.&#xD;
&#xD;
          -  Known immunosuppressive disease, including infection with HIV.&#xD;
&#xD;
          -  Severe medical comorbidities (diabetes mellitus requiring insulin, CHF of any&#xD;
             severity, MI, CVA, or TIA within 3 months of screening visit, unstable angina&#xD;
             pectoris, oxygen-dependent severe pulmonary disease)&#xD;
&#xD;
          -  Subject is currently enrolled in another investigational device or drug trial(s), or&#xD;
             subject has received other investigational agent(s) within 28 days of baseline visit.&#xD;
&#xD;
          -  Subjects who have known hypersensitivity to SADBE or any of its components.&#xD;
&#xD;
          -  Any condition judged by the investigator to cause this clinical trial to be&#xD;
             detrimental to the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena B. Hawryluk</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena B. Hawryluk, MD, PhD</last_name>
    <phone>617-726-5066</phone>
    <email>ehawryluk@partners.org</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elena Hawryluk</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevus</mesh_term>
    <mesh_term>Nevus, Pigmented</mesh_term>
    <mesh_term>Nevus, Epithelioid and Spindle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Squaric acid dibutyl ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

